These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1528 related items for PubMed ID: 10985881

  • 21. BRCA1 and BRCA2 mutations in Danish families with hereditary breast and/or ovarian cancer.
    Thomassen M, Hansen TV, Borg A, Lianee HT, Wikman F, Pedersen IS, Bisgaard ML, Nielsen FC, Kruse TA, Gerdes AM.
    Acta Oncol; 2008; 47(4):772-7. PubMed ID: 18465347
    [Abstract] [Full Text] [Related]

  • 22. Patients with double primary tumors in the breast and ovary- clinical characteristics and BRCA1-2 mutations status.
    Fishman A, Dekel E, Chetrit A, Lerner-Geva L, Bar-Am A, Beck D, Beller U, Ben-Baruch G, Piura B, Friedman E, Struewing JP, Modan B.
    Gynecol Oncol; 2000 Oct; 79(1):74-8. PubMed ID: 11006035
    [Abstract] [Full Text] [Related]

  • 23. BRCA1 and BRCA2 mutations among 233 unselected Finnish ovarian carcinoma patients.
    Sarantaus L, Vahteristo P, Bloom E, Tamminen A, Unkila-Kallio L, Butzow R, Nevanlinna H.
    Eur J Hum Genet; 2001 Jun; 9(6):424-30. PubMed ID: 11436123
    [Abstract] [Full Text] [Related]

  • 24. BRCA1 and BRCA2 mutations account for a large proportion of ovarian carcinoma cases.
    Pal T, Permuth-Wey J, Betts JA, Krischer JP, Fiorica J, Arango H, LaPolla J, Hoffman M, Martino MA, Wakeley K, Wilbanks G, Nicosia S, Cantor A, Sutphen R.
    Cancer; 2005 Dec 15; 104(12):2807-16. PubMed ID: 16284991
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26. Sex ratio distortion in offspring of families with BRCA1 or BRCA2 mutant alleles: an ascertainment bias phenomenon?
    Balmaña J, Díez O, Campos B, Majewski M, Sanz J, Alonso C, Baiget M, Garber JE.
    Breast Cancer Res Treat; 2005 Aug 15; 92(3):273-7. PubMed ID: 16155798
    [Abstract] [Full Text] [Related]

  • 27.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 28. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
    Sarantaus L, Huusko P, Eerola H, Launonen V, Vehmanen P, Rapakko K, Gillanders E, Syrjäkoski K, Kainu T, Vahteristo P, Krahe R, Pääkkönen K, Hartikainen J, Blomqvist C, Löppönen T, Holli K, Ryynänen M, Bützow R, Borg A, Wasteson Arver B, Holmberg E, Mannermaa A, Kere J, Kallioniemi OP, Winqvist R, Nevanlinna H.
    Eur J Hum Genet; 2000 Oct 15; 8(10):757-63. PubMed ID: 11039575
    [Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31. The frequency of germ-line mutations in the breast cancer predisposition genes BRCA1 and BRCA2 in familial prostate cancer. The Cancer Research Campaign/British Prostate Group United Kingdom Familial Prostate Cancer Study Collaborators.
    Gayther SA, de Foy KA, Harrington P, Pharoah P, Dunsmuir WD, Edwards SM, Gillett C, Ardern-Jones A, Dearnaley DP, Easton DF, Ford D, Shearer RJ, Kirby RS, Dowe AL, Kelly J, Stratton MR, Ponder BA, Barnes D, Eeles RA.
    Cancer Res; 2000 Aug 15; 60(16):4513-8. PubMed ID: 10969800
    [Abstract] [Full Text] [Related]

  • 32. Ovarian pathology in risk-reducing salpingo-oophorectomies from women with BRCA mutations, emphasizing the differential diagnosis of occult primary and metastatic carcinoma.
    Rabban JT, Barnes M, Chen LM, Powell CB, Crawford B, Zaloudek CJ.
    Am J Surg Pathol; 2009 Aug 15; 33(8):1125-36. PubMed ID: 19440148
    [Abstract] [Full Text] [Related]

  • 33. Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers.
    Finch A, Shaw P, Rosen B, Murphy J, Narod SA, Colgan TJ.
    Gynecol Oncol; 2006 Jan 15; 100(1):58-64. PubMed ID: 16137750
    [Abstract] [Full Text] [Related]

  • 34. Founder BRCA1 mutations and two novel germline BRCA2 mutations in breast and/or ovarian cancer families from North-Eastern Poland.
    van Der Looij M, Wysocka B, Brozek I, Jassem J, Limon J, Olah E.
    Hum Mutat; 2000 May 15; 15(5):480-1. PubMed ID: 10790213
    [Abstract] [Full Text] [Related]

  • 35. Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutations.
    Wang-Gohrke S, Weikel W, Risch H, Vesprini D, Abrahamson J, Lerman C, Godwin A, Moslehi R, Olipade O, Brunet JS, Stickeler E, Kieback DG, Kreienberg R, Weber B, Narod SA, Runnebaum IB.
    Br J Cancer; 1999 Sep 15; 81(1):179-83. PubMed ID: 10487631
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. CAG and GGC repeat polymorphisms in the androgen receptor gene and breast cancer susceptibility in BRCA1/2 carriers and non-carriers.
    Kadouri L, Easton DF, Edwards S, Hubert A, Kote-Jarai Z, Glaser B, Durocher F, Abeliovich D, Peretz T, Eeles RA.
    Br J Cancer; 2001 Jul 06; 85(1):36-40. PubMed ID: 11437399
    [Abstract] [Full Text] [Related]

  • 40. Chemoprevention options for BRCA1 and BRCA2 mutation carriers.
    Eeles RA, Powles TJ.
    J Clin Oncol; 2000 Nov 01; 18(21 Suppl):93S-9S. PubMed ID: 11060334
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 77.